Emerging treatments for asthma

Expert Opinion on Emerging Drugs

Volumn 8, Issue 1, 2003, Pages 71-81

  Blease, Kate ^a   Lewis, Alan ^a   Raymon, Heather K ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

Asthma; Intracellular signalling; Small molecule inhibitors

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLIC AMP; FLUTICASONE; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; IPRATROPIUM BROMIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONTELUKAST; PHOSPHODIESTERASE; PREDNISOLONE; PREDNISONE; RANTES; ROFLUMILAST; ROLIPRAM; STAT6 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; THEOPHYLLINE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BRONCHODILATATION; CORTICOSTEROID THERAPY; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; HUMAN; NAUSEA; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; VOMITING;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 0038657712     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.1.71     Document Type: Review

References (47)

1. BOUSQUET J, JEFFERY PK, BUSSE WW, JOHNSON M, VIGNOLA AM: Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med (2000) 161:1720-1745.
2. LAZARUS SC: Inflammation, inflammatory mediators, and mediator antagonists in asthma. J. Clin. Pharmacol. (1998) 38:577-582.
3. CHIAPPARA G, GAGLIARDO R, SIENA A et al.: Airway remodelling in the pathogenesis of asthma. Curr. Opin. Allergy Clin. Immunol. (2001) 1:85-93.
4. SALVI S: Pollution and allergic airways disease. Curr. Opin. Allergy Clin. Immunol. (2001) 1:35-41.
5. GIEMBYCZ MA, CORRIGAN CJ, SEYBOLD J, NEWTON R, BARNES PJ: Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. (1996) 118:1945-1958.
6. WANG P, WU P, OHLETH KM, EGAN RW, BILLAH MM: Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol. Pharmacol. (1999) 56:170-174.
7. TORPHY TJ: Phosphodiesterase isoenzymes - molecular targets for novel anti-asthma agents. Am. J. Respir. Crit. Care Med. (1998) 157:351-370.
8. KOTSIMBOS TC, ERNST P, HAMID QA: Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. Proc. Assoc. Am. Physicians (1996) 108:368-373.
9. BODEY KJ, SEMPER AE, REDINGTON AE et al.: Cytokine profiles of BAL T cells and T-cell clones obtained from human asthmatic airways after local allergen challenge. Allergy (1999) 54:1083-1093.
10. YUYAMA N, DAVIES DE, AKAIWA M et al.: Analysis of novel disease-related genes in bronchial asthma. Cytokine (2002) 19:287-296.
11. KUMAR RK, HERBERT C, YANG M et al.: Role of interleukin-13 in eosinophil accumulation and airway remodeling in a mouse model of chronic asthma. Clin. Exp. Allergy (2002) 32:1104-1111.
12. KUPERMAN DA, HUANG X, KOTH LL et al.: Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat. Med (2002) 8:885-889.
13. BLEASE K, JAKUBZICK C, WESTWICK J et al.: Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J. Immunol. (2001) 166:5219-5224.
14. BLEASE K, JAKUBZICK C, SCHUH JM et al.: IL-13 fusion cytotoxin ameliorates chronic fungal-induced allergic airway disease in mice. J. Immunol. (2001) 167:6583-6592.
15. HAMELMANN E, GELFAND EW: IL-5-induced airway eosinophilia-the key to asthma? Immunol. Rev. (2001) 179:182-191.
16. FOSTER PS, HOGAN SP, RAMSAY AJ, MATTHAEI KI, YOUNG IG: Interleukin 5 deficiency abolishes eosinophila, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. (1996) 183:195-201.
17. VERMEER PD, HARSON R, EINWALTER LA, MONINGER T, ZABNER J: Interleukin-9 induces goblet cell hyperplasia during repair of human airway epithelia. Am. J. Respir. Cell Mol. Biol. (2003) 28:286-295.
18. MCMILLAN SJ, BISHOP B, TOWNSEND MJ, MCKENZIE AN, LLOYD CM: The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. J. Exp. Med. (2002) 195:51-57.
19. CHENG G, ARIMA M, HONDA K et al.: Anti-interleukin-9 antibody treatments inhibits airway inflammation and hyperreactivity in mouse asthma model. Am. J. Respir. Crit. Care Med (2002) 166:409-416,
20. MAZZARELLA G, BIANCO A, CATENA E, DE PALMA R, ABBATE GF: Th1/Th2 lymphocyte polarization in asthma. Allergy (2000) 55:6-9.
21. TOURNOY KG, KIPS JC, PAUWELS RA: Is Th1 the solution for Th2 in asthma? Clin. Exp. Allergy (2002) 32:17-29.
22. LEONARD P, SUR S: Interleukin-12: potential role in asthma therapy. Biodrugs (2003) 17:1-7.
23. GANGUR V, OPPENHEIM JJ: Are chemokines essential or secondary participants in allergic responses? Ann. Allergy Asthma Immunol. (2000) 84:569-581.
24. BUHL R: Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review. Respir. Med. (2003) 97:123-129.
25. HEINLY CS, SEMPOWSKI GD, LEE DM et al.: Comparison of thymocyte development and cytokine production in CD7-deficient, CD28-deficient and CD7/CD28 double-deficient mice. Int. Immunol. (2001) 13:157-166.
26. DRIVER AG, KUKOLY CA, ALI S, MUSTAFA SJ: Adenosine in bronchoalveolar lavage fluid in asthma. Am. Rev. Respir. Dis. (1993) 148:91-97.
27. CARLOS TM, HARLAN JM: Leukocyte-endothelial adhesion molecules. Blood (1994) 84:2068-2101.
28. BLOEMEN PG, HENRICKS PA, NIJKAMP FP: Cell adhesion molecules and asthma. Clin. Exp. Allergy (1997) 27:128-141.
29. HORNER AA, RAZ E: Immunostimulatoty sequence oligonucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic disease. J. Allergy Clin. Immunol. (2002) 110:706-712.
30. BARNES PJ, ADCOCK IM: Transcription factors and asthma. Eur. Respir. J. (1998) 12:221-234.
31. DONG C, DAVIS RJ, FLAVELL RA: MAP kinases in the immune response. Ann. Rev. Immunol. (2002) 20:55-57. An excellent review on MAP kinases.
32. ESCOTT KJ, BELVISI MG, BIRRELL MA: Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat. Br. J. Pharmacol. (2000) 131:173-176.
33. UNDERWOOD DC, OSBORN RR, KOTZER CJ et al.: SB 239063, a potent p38 MAP kinase inhibitor reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J. Pharmacol. Exp. Ther. (2000) 293:281-288.
34. WESTON CR, DAVIS RJ: The JNK signal transduction pathway. Curr. Opin. Genet. Dev. (2002) 12:14-21.
35. BENNETT BL, SASAKI DT, MURRAY BW et al.: SP600125, an anthrapyrazolone inhibitor of jun N-terminal kinase. Proc. Natl. Acad. Sci. USA (2001) 98:13681-13686. First report describing a small molecule, selective, JNK inhibitor.
36. HUBBARD SR, TILL JH: Protein tyrosine kinase structure and function. Ann. Rev. Biochem. (2000) 69:373-398.
37. HUANG TJ, ADCOCK IM, CHUNG KF: A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen-exposed rat. Br. J. Pharmacol. (2001) 134:1029-1036.
38. PERNIS AB, ROTHMAN PB: JAK-STAT signaling in asthma. J. Clin. Invest. (2002) 109:1279-1283.
39. AKIMOTO T, NUMATA F, TAMURA M et al.: Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J. Exp. Med (1998) 187:1537-1542.
40. MIYATA S, MATSUYAMA T, KODAMA T et al.: STAT6 deficiency in a mouse model of allergen-induced airways inflammation abolishes eosinophilia but induces infiltration of CD8+ T cells. Clin. Exp. Allergy (1999) 29:114-123.
41. SHIMODA K, VAN DEURSEN J, SANGSTER MY et al.: Lack of IL-4- induced Th2 response and IgE class switching in mice with disrupted STAT6 gene. Nature (1996) 380:630-633.
42. MULLINGS RE, WILSON SJ, PUDDICOMBE SM et al.: Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium. J. Allergy Clin. Immunol. (2001) 108:832-838.
43. VAN EERDEWEGH P, LITTLE RD, DUPUIS J et al.: Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature (2002) 418:426-430. An interesting paper describing the association between ADAM33 gene and asthma.
44. ECONOMIDES AN, CARPENTER LR, RUDGE JS et al.: Cytokine traps: multi-component, high affinity blockers of cytokine action. Nat. Med. (2003) 9:47-52. An interesting paper describing a novel mechanism for blockade of cytokine action.
45. CORREN J, CASALE T, DENIZ Y, ASHBY M: Omalizumab, a recombinant humanized and-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J. Allergy Clin. Immunol. (2003) 111:87-90.
46. NYCE JW, METZGER WJ: DNA antisense therapy for asthma in an animal model. Nature (1997) 385:721-725.
47. KLINE JN: Effects of CpG DNA on Th1/Th2 balance in asthma. Curr. Top. Microbiol. Immunol. (2000) 247:211-225.